1. Updates on the Prevention and Management of CINV

2. Topics Covered

3. Types of CINV

4. Emetogenic Potential of Regimens

5. Patient-Related Risk Factors

6. Why It Is Important to Prevent CINV

7. What Does Prophylaxis Involve?

8. Therapies for Preventing or Treating CINV

9. Clinical Practice Guidelines for Preventing and Managing CINV

10. MASCC Recommendations for Preventing Acute Nausea and Vomiting

11. MASCC Recommendations for Delayed Nausea and Vomiting

12. Challenges: Nonadherence to Practice Guidelines

13. Clark-Snow et al Findings

14. More Recently Approved Therapies

15. Rolapitant: Schwartzberg et al

16. Rolapitant: Schwartzberg et al (cont)

17. Rolapitant: Rapoport et al

18. Rolapitant: Navari et al

19. Rolapitant: Aapro et al

20. NEPA: Approval

21. NEPA: Gralla et al Phase 3 Trial

22. NEPA: Aapro et al Phase 3 Trial

23. NEPA: Feyer et al

24. NEPA: Aapro et al Post Hoc Safety Analysis

25. Palonosetron in Triplet Regimen

26. Palonosetron in Triplet Regimen (cont)

27. Aprepitant: Kang et al

28. Kang et al: CR Rate

29. Olanzapine: Navari et al

30. Navari et al Study Findings

31. Navari et al Study Findings (cont)

32. Olanzapine: Chiu et al

33. APF530: A New 5-HT3 RA Formulation

34. Updated Clinical Practice Guidelines

35. Updated ASCO Guidelines

36. Summary of Key Points

37. Abbreviations

38. Abbreviations (cont)